PubMed · 7704753
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D L Kleinberg. 1994. Galactorrhea.. https://pubmed.ncbi.nlm.nih.gov/7704753/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A gas chromatographic procedure with flame ionization detection for the simultaneous determination of diisopyramide and butyrophenones in plasma was developed and evaluated. The quantitative analysis of diisopyramide and butyrophenones (BTPs) was performed in gas chromatograph equipped with packed column (glass column packed with 3% of phenylmethyl silicone-20% ph.), with previous Solid Phase Extraction (SPE) of drugs in C18 minicolumns. For all the drugs considered the accuracy of the proposed method has been evaluated through the recovery test which fell in the range 93-99%, once the absence of matrix interferences has been verified. The precision, expressed as coefficient of variation (CV%), has been of the order of 4%. A 15 m x 0.32 mm i.d. crosslinked, 5% phenylmethyl silicone-coated fused-silica column was also quantitatively utilized and samples were injected using the on-column mode.
Partial least-squares calibration was used for the spectrophotometric determination of the active compound and preservative in a syrup also containing several light absorbing excipients. The calibration matrix was constructed from laboratory-made mixtures of the analytes and excipients and was used to quantify three samples from different batches. The most suitable conditions for quantitation were determined and the results obtained are compared with those provided by HPLC.
Ebastine is a new piperidine-containing, relatively nonsedating second-generation H1-receptor antagonist. In a double-blind, parallel-group study of a single 5 mg or 10 mg dose of ebastine syrup used to treat allergic rhinitis in 20 children aged 6 to 12 years, we tested the hypothesis that the medication would have a duration of action of at least 24 hours. We measured plasma concentrations of carebastine, the pharmacologically active metabolite of ebastine, and the wheals and flares produced by epicutaneous tests with histamine phosphate, 1.0 mg/ml. Ebastine was absorbed well; peak carebastine concentrations occurred approximately 3 hours after dosing. Mean plasma elimination half-life values of carebastine ranged from 10 to 14 hours. The pharmacokinetics of carebastine were linear and dose independent in the dosage range studied. After the 5 or 10 mg dose, there were no significant differences between mean plasma elimination half-life values, mean oral clearance values, or mean apparent volumes of distribution. Mean peak plasma carebastine concentrations and mean areas under the plasma carebastine concentration-time curve after the 10 mg dose were 1.93 and 1.76 times, respectively, the values obtained after the 5 mg dose. Both doses significantly reduced the histamine-induced wheal-and-flare areas for up to 28 hours compared with predose values. The differences in effect between the doses generally were not statistically or clinically significant. No adverse effects were noted. We conclude that ebastine, an effective H1-receptor antagonist with a prompt onset of action and a long duration of action, is suitable for once-daily administration to children.